Low-add Multifocal vs. Monofocal IOLs
Launched by PRIM. PROF. DR. OLIVER FINDL, MBA · Nov 20, 2018
Trial Information
Current as of June 12, 2025
Unknown status
Keywords
ClinConnect Summary
Spectacle independence is one of the main aims in modern cataract surgery. Although bilateral monofocal IOL implantation, aiming for emmetropia or low myopia, leads to high levels of patient satisfaction in distance vision, spectacle dependence for intermediate vision, reading and other near vision tasks is the usual result.
There are different techniques to reduce spectacle dependence, the most common one is the use of multifocal IOLs. However, a variable number of patients complain of problems, such as glare or haloes (positive dysphotopsia symptoms). Dysphotopsia symptoms may vary signi...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age-related cataract in both eyes
- • Scheduled for bilateral cataract surgery
- • Motivated to be less spectacle dependant in the distance to intermediate vision range
- • Patients with an expected BCDVA of 0.8 snellen score or better after surgery
- • Patients with the need of an IOL Power in the range of 10 to 30D (biometry performed with the IOL master 700)
- • Age 21 and older
- • Written informed consent prior to recruitment
- Exclusion Criteria:
- • Pregnancy (pregnancy test will be taken pre-operatively in women of reproductive age)
- • Retinopathia pigmentosa
- • Chronic uveitis
- • Amblyopia
- • Pupil decentration \> 1mm center shift
- • preceded retinal surgery
- • preceded Laser-in-situ-Keratomileusis (LASIK)
- • Any ophthalmic abnormality that could compromise visual function or the measurements
About Prim. Prof. Dr. Oliver Findl, Mba
Prim. Prof. Dr. Oliver Findl, MBA, is a distinguished clinical trial sponsor renowned for his expertise in ophthalmology and a strong commitment to advancing medical research. With a robust academic background and extensive clinical experience, he leads innovative studies aimed at improving patient outcomes and fostering breakthroughs in eye care. Dr. Findl combines his clinical acumen with a strategic approach to trial management, ensuring rigorous adherence to ethical standards and regulatory compliance. His dedication to collaboration and excellence positions him as a trusted partner in the development of transformative therapies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Vienna, , Austria
Vienna, , Austria
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials